: In the past decades, several treatments have been proposed for the management of metastatic renal cell carcinoma (mRCC). Among these, cytoreductive nephrectomy (CN) represents a controversial and open issue in the era of targeted therapy and novel immunotherapy with immune checkpoint inhibitors. Two important studies, CARMENA and SURTIME, analyzed therapy with sunitinib with or without CN, and immediate CN followed by sunitinib versus a deferred CN after three cycles of sunitinib, respectively. CARMENA showed the non-inferiority of sunitinib alone versus sunitinib plus CN, whereas SURTIME showed no difference in progression-free survival (PFS), but a better median OS among patients with deferred CN. Therefore, more prospective clinical trials and appropriate patient identification are necessary to support CN in this new scenario. This review provides a snapshot of the current evidence for CN in mRCC, discusses the management strategies, and offers perspectives on the direction of future research.

Cytoreductive Nephrectomy and Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives / Napolitano, Luigi; Manfredi, Celeste; Cirillo, Luigi; Fusco, Giovanni Maria; Passaro, Francesco; Abate, Marco; La Rocca, Roberto; Mastrangelo, Francesco; Spirito, Lorenzo; Pandolfo, Savio Domenico; Crocetto, Felice; Arcaniolo, Davide; Barone, Biagio. - In: MEDICINA. - ISSN 1648-9144. - 59:4(2023), p. 767. [10.3390/medicina59040767]

Cytoreductive Nephrectomy and Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives

Napolitano, Luigi;Cirillo, Luigi;Fusco, Giovanni Maria;Passaro, Francesco;Abate, Marco;La Rocca, Roberto;Mastrangelo, Francesco;Spirito, Lorenzo;Pandolfo, Savio Domenico;Crocetto, Felice;Barone, Biagio
2023

Abstract

: In the past decades, several treatments have been proposed for the management of metastatic renal cell carcinoma (mRCC). Among these, cytoreductive nephrectomy (CN) represents a controversial and open issue in the era of targeted therapy and novel immunotherapy with immune checkpoint inhibitors. Two important studies, CARMENA and SURTIME, analyzed therapy with sunitinib with or without CN, and immediate CN followed by sunitinib versus a deferred CN after three cycles of sunitinib, respectively. CARMENA showed the non-inferiority of sunitinib alone versus sunitinib plus CN, whereas SURTIME showed no difference in progression-free survival (PFS), but a better median OS among patients with deferred CN. Therefore, more prospective clinical trials and appropriate patient identification are necessary to support CN in this new scenario. This review provides a snapshot of the current evidence for CN in mRCC, discusses the management strategies, and offers perspectives on the direction of future research.
2023
Cytoreductive Nephrectomy and Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives / Napolitano, Luigi; Manfredi, Celeste; Cirillo, Luigi; Fusco, Giovanni Maria; Passaro, Francesco; Abate, Marco; La Rocca, Roberto; Mastrangelo, Francesco; Spirito, Lorenzo; Pandolfo, Savio Domenico; Crocetto, Felice; Arcaniolo, Davide; Barone, Biagio. - In: MEDICINA. - ISSN 1648-9144. - 59:4(2023), p. 767. [10.3390/medicina59040767]
File in questo prodotto:
File Dimensione Formato  
medicina-59-00767-v2.pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Licenza: Dominio pubblico
Dimensione 311.29 kB
Formato Adobe PDF
311.29 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/920051
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 9
social impact